Filing Details
- Accession Number:
- 0001209191-18-041045
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-07-03 16:20:59
- Reporting Period:
- 2018-07-02
- Accepted Time:
- 2018-07-03 16:20:59
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 820081 | Cambrex Corp | CBM | Pharmaceutical Preparations (2834) | 222476135 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1192621 | M Steven Klosk | One Meadowlands Plaza East Rutherford NJ 07073 | President & Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-07-02 | 25,000 | $12.46 | 188,328 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2018-07-02 | 30,000 | $16.91 | 218,328 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-07-02 | 30,642 | $51.45 | 187,686 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-07-02 | 24,358 | $52.08 | 163,328 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Acquisiton | 2018-07-02 | 25,000 | $0.00 | 25,000 | $12.46 |
| Common Stock | Stock Option (right to buy) | Acquisiton | 2018-07-02 | 30,000 | $0.00 | 30,000 | $16.91 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2019-10-24 | No | 4 | M | Direct | |
| 50,000 | 2020-10-28 | No | 4 | M | Direct |
Footnotes
- The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.975 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 2 to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.00 to $52.35 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 3 to this Form 4.
- The option representing a right to purchase 80,000 shares became exercisable in four equal installments beginning October 24, 2013, which was the first anniversary of the date on which the option was granted.
- The option representing a right to purchase 80,000 shares became exercisable in four equal installments beginning October 28,2014, which was the first anniversary of the date on which the option was granted.
Billionaire Hedge Funds
